Seminars in Hematology
Volume 45, Issue 4 , Pages 267-275 , October 2008

Erythropoietic Agents and the Elderly

  • Neeraj Agarwal
    • ,
  • Josef T. Prchal

      Affiliations

    • Corresponding Author InformationAddress correspondence to Josef T. Prchal, MD, Hematology Division, 30 North 1900 East, SOM 5C402, Salt Lake City, UT 84132

References 

  1. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood. 1988;71:524–527
  2. Koury ST, Bondurant MC, Koury MJ, Semenza GL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood. 1991;77:2497–2503
  3. D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell. 1989;57:277–285
  4. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990;248:378–381
  5. Kelley LL, Koury MJ, Bondurant MC, Koury ST, Sawyer ST, Wickrema A. Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production. Blood. 1993;82:2340–2352
  6. Lin CS, Lim SK, D'Agati V, Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev. 1996;10:154–164
  7. Rice L, Alfrey CP. The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. Cell Physiol Biochem. 2005;15:245–250
  8. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990;87:5978–5982
  9. Fraser JK, Tan AS, Lin FK, Berridge MV. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol. 1989;17:10–16
  10. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol. 2001;60:386–392
  11. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development. 1999;126(16):3597–3605
  12. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem. 1998;273:25381–25387
  13. Juul SE, Zhao Y, Dame JB, Du Y, Hutson AD, Christensen RD. Origin and fate of erythropoietin in human milk. Pediatr Res. 2000;48:660–667
  14. Magnanti M, Gandini O, Giuliani L, Gazzaniga P, Marti HH, Gradilone A, et al. Erythropoietin expression in primary rat Sertoli and peritubular myoid cells. Blood. 2001;98:2872–2874
  15. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int. 2006;70:246–250
  16. Agarwal N, Gordeuk VR, Prchal JT. Are erythropoietin receptors expressed in tumors? (Facts and fiction—More careful studies are needed). J Clin Oncol. 2007;25:1813–1814
  17. Yoon D, Agarwal N, Prchal JT. Does erythropoietin promote tumor growth?. Clin Cancer Res. 2008;14:1920
  18. Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE. 2007;2:e549
  19. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141:14–31
  20. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92:5510–5514
  21. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nature Genet. 2002;32:614–621
  22. Semenza G. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 2001;13:167–171
  23. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275
  24. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIF alfa targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 2001;292:464–468
  25. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alfa to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468–472
  26. Gordeuk V, Sergueeva AI, Miasnikova GY, Okhotin D, Voloshin Y, Choyke PL, et al. Congenital disorder of oxygen sensing: Association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood. 2004;103:3924–3932
  27. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, et al. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A. 1999;96:12436–12441
  28. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006;59:15–26
  29. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A. 2007;104:2301–2306
  30. Chavez JC, Baranova O, Lin J, Pichiule P. The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci. 2006;26:9471–9481
  31. Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117:1068–1077
  32. Sanchez M, Galy B, Muckenthaler MU, Hentze MW. Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol. 2007;14:420–426
  33. Percy MJ, Furlow PW, Lucas GS, Li X, Lappin TR, McMullin MF, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008;358:162–168
  34. Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell. 2007;131:309–323
  35. Liu YV, Hubbi ME, Pan F, McDonald KR, Mansharamani M, Cole RN, et al. Calcineurin promotes hypoxia-inducible factor 1alpha expression by dephosphorylating RACK1 and blocking RACK1 dimerization. J Biol Chem. 2007;282:37064–37073
  36. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood. 2001;98:3626–3634
  37. Goldwasser E, Kung CK, Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem. 1974;249:4202–4206
  38. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Experimental Hematol. 2003;31:290–299
  39. Beutel G, Ganser A. Risks and benefits of erythropoiesis-stimulating agents in cancer management. Semin Hematol. 2007;44:157–165
  40. FDAUSFaDA. http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01740.htmlAccessed April 5, 2008
  41. FDAUSFaDA. http://www.fda.gov/medwatch/safety/2007/safety07.htm#ESADrugs and Therapeutic Biological Products (CDER). Accessed April 6, 2008
  42. Procrit (epoetin alfa) full prescribing information. http://www.procrit.com/procrit/shared/OBI/PI/ProcritBooklet.pdf#page=1Accessed April 6, 2008
  43. Reocormon (Epoetin beta) full prescribing information. http://www.medsafe.govt.nz/profs/Datasheet/r/Recormoninj.htmAccessed April 6, 2008
  44. Aranesp (darbepoetin alpha) full prescribing information. http://www.aranesp.com/Accessed April 6, 2008
  45. Kwan JT, Pratt RD. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin. 2007;23:307–311
  46. Martin KJ. The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease. Clin Nephrol. 2007;68:26–31
  47. Macdougall IC. CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436–440
  48. Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol. 2007;47:1390–1397
  49. Hirsh V, Glaspy J, Mainwaring P, Manegold C, Ramlau R, Eid JE. Phase II study of two dose schedules of C.E.R.A. (continuous erythropoietin receptor activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Trials. 2007;8:8
  50. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637–646
  51. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (MAXIMA). Lancet. 2007;370:1415–1421
  52. Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007;110:2140–2147
  53. Bernhardt W, Wiesener MS, Schmieder RE, Gunzler V, Eckardt KU, et al. The prolyl hydroxylase inhibitor FG-2216 stimulates EPO production in nephric and anephric dialysis patients—Evidence for an underutilized production capacity in liver and kidneys. American Society of Nephrology Renal Week. 2007;San Francisco, CA, November 2-5, (abstr SA-PO784)
  54. Frohna P, Milwee S, Pinkett J, Lee T, Moore-Perry K, Chou J, et al. Results from a randomized, single-blind, placebo-controlled trial of FG-4592, a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in CKD anemia. American Society of Nephrology Renal Week. 2007;San Francisco, CA, November 2-5, (abstr SU-PO806)
  55. Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Hoey K, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry. 1998;37:3699–3710
  56. Macdougall IC. Novel erythropoiesis-stimulating agents: A new era in anemia management. Clin J Am Soc Nephrol. 2008;3:200–207
  57. Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006;34:1303–1311
  58. Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006;108:1830–1834
  59. Macdougall I, Tucker B, Yaqoob M, Mikhail A, Nowicki M, MacPhee I, et al. Hematide, a synthetic peptide-based erythropoiesis stimulating agent, achieves correction of anemia and maintains hemoglobin in patients with chronic kidney disease not on dialysis. Annual meeting of the American Society of Nephrology, San Diego, CA. 2006;November 14-19, (abstr F-FC079)
  60. Besarab A, Zeig S, Geronemus R, Pergola P, Whittier F, Zabaneh R, et al. Hematide, a synthetic peptide-based erythropoiesis stimulating agent, maintains hemoglobin in hemodialysis patients previously treated epoetin alfa. National Kidney Foundation Spring Clinical Meeting, Orlando, FL. 2007;April 10-14, (abstr 99)
  61. Pickering L, Cwiertka K, Jassem J, Petera J, Pettengell R, Ramlau R, et al. Correction of anemia with Hematide, a synthetic peptide-based erythropoiesis stimulating agent (ESA), in oncology patients receiving chemotherapy. Blood. 2007;110:(abstr 3666)
  62. Woodburn KW, Fan Q, Winslow S, Chen MJ, Mortensen RB, Casadevall N, et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol. 2007;35:1201–1208
  63. Bugelski PJ, Capocasale RJ, Makropoulos D, Marshall D, Fisher PW, Lu J, et al. CNTO 530: Molecular pharmacology in human UT-7(EPO) cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol. 2008;134:171–180
  64. Nakano Y, Imagawa S, Matsumoto K, Stockmann C, Obara N, Suzuki N, et al. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood. 2004;104:4300–4307
  65. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR. Controlling signal transduction with synthetic ligands. Science. 1993;262:1019–1024
  66. Neff T, Blau CA. Pharmacologically regulated cell therapy. Blood. 2001;97:2535–2540
  67. Weinreich MA, Lintmaer I, Wang L, Liggitt HD, Harkey MA, Blau CA. Growth factor receptors as regulators of hematopoiesis. Blood. 2006;108:3713–3721
  68. Neff T, Horn PA, Valli VE, Gown AM, Wardwell S, Wood BL, et al. Pharmacologically regulated in vivo selection in a large animal. Blood. 2002;100:2026–2031
  69. Nagasawa Y, Wood BL, Wang L, Lintmaer I, Guo W, Papayannopoulou T, et al. Anatomical compartments modify the response of human hematopoietic cells to a mitogenic signal. Stem Cells. 2006;24:908–917
  70. Chen ZY, Asavaritikrai P, Prchal JT, Noguchi CT. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J BiolChem. 2007;282:25875–25883
  71. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004;101:14907–14912
  72. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412:641–647
  73. Genc S, Koroglu TF, Genc K. Erythropoietin and the nervous system. Brain Res. 2004;1000:19–31
  74. Lee ST, Chu K, Sinn DI, Jung KH, Kim EH, Kim SJ, et al. Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage. J Neurochem. 2006;96:1728–1739
  75. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A. 2004;101:823–828
  76. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782–792
  77. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495–505
  78. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130:2577–2588
  79. Blau CA. Erythropoietin in cancer: Presumption of innocence?. Stem Cells. 2007;25:2094–2097
  80. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 2006;107:1892–1895
  81. Necas E, Prchal JT. The diverse functions of Lipocalin: A recently-recognized mediator of transferrin independent iron transport, innate immunity, and cancer signaling. Hematologist. 2006;3:3
  82. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Scie U S A. 2006;103:14901–14906
  83. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–924
  84. Kimel M, Leidy NK, Mannix S, Dixon J. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? (Summary of trials of cancer, HIV/AIDS, and chronic kidney disease). Value Health. 2008;11:57–75
  85. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55:808–820
  86. Fliser D, Haller H. Erythropoietin and treatment of non-anemic conditions—Cardiovascular protection. Semin Hematol. 2007;44:212–217
  87. Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004;110:1006–1012
  88. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999–1007
  89. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J. 2007;28:2018–2027
  90. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med Aug. 1998;339:584–590
  91. Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526–535
  92. Prchal JT, Semenza GL, Prchal J, Sokol L. Familial polycythemia. Science. 1995;268:1831–1832
  93. Gordeuk VR, Sergueeva AI, Miasnikova GY, Okhotin D, Voloshin Y, Choyke PL, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood. 2004;103:3924–3932
  94. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708–714
  95. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  96. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al. Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA. 2002;288:2827–2835
  97. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357:965–976
  98. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood. 2004;104:2263–2268
  99. Guralnik JM, Ershler WB, Schrier SL, Picozzi VJ. Anemia in the elderly: A public health crisis in hematology. Hematology Education Program of the American Society of Hematology American Society of Hematology. 2005;528–532
  100. Nilsson-Ehle H, Jagenburg R, Landahl S, Svanborg A. Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol. 2000;65:297–305
  101. Penninx BW, Pahor M, Cesari M, Corsi AM, Woodman RC, Bandinelli S, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc. 2004;52:719–724
  102. Cesari M, Penninx BW, Lauretani F, Russo CR, Carter C, Bandinelli S, et al. Hemoglobin levels and skeletal muscle: Results from the InCHIANTI study. J Gerontol. 2004;59:249–254
  103. Lucca U, Tettamanti M, Mosconi P, Apolone G, Gandini F, Nobili A, et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the “Health and Anemia” study. PLoS ONE. 2008;3:e1920
  104. Denny SD, Kuchibhatla MN, Cohen HJ. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med. 2006;119:327–334
  105. Semba RD, Ricks MO, Ferrucci L, Xue QL, Chaves P, Fried LP, et al. Types of anemia and mortality among older disabled women living in the community: The Women's Health and Aging Study I. Aging Clin Exp Res. 2007;19:259–264
  106. Ershler WB, Sheng S, McKelvey J, Artz AS, Denduluri N, Tecson J, et al. Serum erythropoietin and aging: a longitudinal analysis. J Am Geriatr Soc. 2005;53:1360–1365
  107. Ershler WB, Chen K, Reyes EB, Dubois R. Economic burden of patients with anemia in selected diseases. Value Health. 2005;8:629–638

PII: S0037-1963(08)00116-9

doi: 10.1053/j.seminhematol.2008.06.007

Seminars in Hematology
Volume 45, Issue 4 , Pages 267-275 , October 2008

Article Tools

* Image Usage & Resolution